ARTICLE | Finance
Pharma seeking efficiencies, agility as it looks to boost profits in 2025 and beyond
By Paul Bonanos, Director of Biopharma Intelligence
May 10, 2024 6:37 PM UTC
Deepened commitments to data and artificial intelligence are part of a program Takeda is implementing to spur growth and improve margins, the pharma said as it presented full fiscal-year earnings Thursday.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) said its new, unnamed program is meant to improve efficiency and organizational agility, following what President and CEO Christophe Weber called a “well-managed but tough year” during its earnings call. Takeda’s fiscal 2023 ended March 31, 2024…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652401/investments-in-digital-ai-tech-will-be-part-of-takeda-s-return-to-growth-program